📊 67 views
🗝️ Key Points
- Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since.
- The company expects to begin making medicines at all four facilities Within five years. That added production capacity for Eli Lilly’s obesity pill, orforglipron, is.
- as President Donald Trump threatens to impose tariffs on pharmaceuticals imported into the U.S.
It is the second in a string of new planned U.S. investments by the drugmaker. Eli Lilly announced in February that it would spend at least $27 billion to build four new domestic manufacturing plants, adding to $23 billion in previous investments since 2020.
Eli Lilly said it will announce the two remaining U.S. sites this year. The company expects to begin making medicines at all four facilities within five years…